Dapagliflozin (5mg), Vildagliptin SR (50mg) .............

Introduction to DAPA VILDA 50/5

DAPA VILDA 50/5 is a combination medication that combines Dapagliflozin (5mg), a SGLT-2 inhibitor, and Vildagliptin SR (50mg), a DPP-4 inhibitor, both of which are used in the treatment of type 2 diabetes. This combination therapy is designed to improve blood sugar control and help manage diabetes, a chronic condition that affects how your body metabolizes glucose.

DAPA VILDA 50/5 is a fixed-dose combination of Dapagliflozin and Vildagliptin, two widely used drugs in the management of type 2 diabetes mellitus (T2DM). Type 2 diabetes is a metabolic disorder characterized by insulin resistance and insufficient insulin production. Over time, this leads to high blood sugar levels that can damage organs and tissues. The goal of treatment is to lower blood sugar levels and prevent the complications associated with diabetes.In this article, we will discuss the ingredients, key benefits, how DAPA VILDA 50/5 works, dosage, side effects, and more, in detail. We will also explore how this medication fits into the broader management of diabetes and its role in improving quality of life for patients.

The Active Ingredients in DAPA VILDA 50/5

1. Dapagliflozin (5mg)
   Dapagliflozin is an SGLT-2 inhibitor, which stands for Sodium-Glucose Co-Transporter-2. It works by blocking the SGLT-2 proteins in the kidneys, which are responsible for reabsorbing glucose from urine back into the bloodstream. By inhibiting these proteins, Dapagliflozin helps to reduce blood glucose levels by allowing excess glucose to be excreted through urine. This process not only lowers blood sugar levels but also provides a mild diuretic effect, which can aid in controlling blood pressure.

2. Vildagliptin SR (50mg)
   Vildagliptin is a DPP-4 inhibitor (dipeptidyl peptidase-4 inhibitor). DPP-4 is an enzyme that breaks down incretin hormones, which are involved in regulating insulin secretion in response to meals. By inhibiting this enzyme, Vildagliptin enhances the action of incretin hormones, improving insulin secretion when blood sugar is elevated and inhibiting glucagon release, which helps to lower blood sugar levels. Vildagliptin SR refers to the sustained release formulation of the drug, providing a steady release of the medication throughout the day to maintain better blood glucose control.

Key Benefits of DAPA VILDA 50/5

The combination of Dapagliflozin and Vildagliptin offers several key benefits in the management of type 2 diabetes, making it an effective treatment option for many patients. Here are some of the primary benefits:

1. Improved Blood Sugar Control
   The primary benefit of DAPA VILDA 50/5 is its ability to improve blood sugar control in patients with type 2 diabetes. Dapagliflozin works by eliminating excess glucose through urine, while Vildagliptin helps to enhance insulin secretion and lower glucagon levels. Together, they effectively reduce fasting blood glucose and postprandial (after meal) glucose levels, contributing to better overall blood sugar management.

2. Weight Loss
   One of the significant advantages of Dapagliflozin is its ability to help with weight loss. As excess glucose is excreted through urine, it also results in a slight reduction in body weight. This can be beneficial for patients with type 2 diabetes who often struggle with obesity or overweight, conditions that can further complicate diabetes management.

3. Lower Blood Pressure
   Dapagliflozin has been shown to have a mild diuretic effect, helping reduce blood pressure. For patients with type 2 diabetes, who are at an increased risk of hypertension (high blood pressure), this additional benefit can contribute to better cardiovascular health.

4. Cardiovascular Protection
   Research has demonstrated that Dapagliflozin has cardiovascular protective effects, making it particularly useful in patients with diabetes and heart disease. It has been shown to reduce the risk of hospitalization due to heart failure, making it an important drug for patients with both diabetes and cardiovascular disease.

5. Reduced Risk of Hypoglycemia
   Unlike some other diabetes medications, DAPA VILDA 50/5 has a lower risk of causing hypoglycemia (low blood sugar). This is because Vildagliptin only enhances insulin secretion in response to elevated blood glucose levels, reducing the risk of excess insulin production when blood sugar levels are normal or low.

How Does DAPA VILDA 50/5 Work?

The combination of Dapagliflozin and Vildagliptin works in different ways to control blood glucose levels:

1. Dapagliflozin (SGLT-2 Inhibition)
   By inhibiting the SGLT-2 proteins in the kidneys, Dapagliflozin prevents the reabsorption of glucose back into the bloodstream, causing excess glucose to be excreted through urine. This leads to lower blood sugar levels and can also result in a slight decrease in body weight due to the loss of calories through urine.

2. Vildagliptin (DPP-4 Inhibition)
   Vildagliptin works by inhibiting the DPP-4 enzyme, which in turn increases the levels of incretin hormones. These hormones help regulate insulin production in response to food intake. By enhancing insulin secretion when blood glucose levels are high and reducing glucagon (a hormone that raises blood sugar), Vildagliptin helps improve overall blood glucose control.

Together, these two drugs provide a complementary mechanism of action, addressing both the insulin resistance and insufficient insulin production aspects of type 2 diabetes.

Dosage of DAPA VILDA 50/5

The standard dose of DAPA VILDA 50/5 is one tablet per day. This dosage should be taken as prescribed by the healthcare provider. The tablet should be taken with or without food, typically at the same time each day to help patients remember to take it consistently.

For patients who have not previously been treated with either Dapagliflozin or Vildagliptin, doctors may start with a lower dose and gradually increase it to assess tolerance and minimize side effects.

Important Considerations for Dosage:

• Renal Function: Dapagliflozin is cleared from the body via the kidneys. It is not recommended for patients with severe kidney impairment (e.g., those with an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m²). Dosage adjustments may be necessary based on kidney function.
• Hypoglycemia Risk: Since DAPA VILDA 50/5 carries a lower risk of hypoglycemia compared to other diabetes medications, it can be used safely in patients who are at risk of low blood sugar. However, combination with other antidiabetic drugs such as sulfonylureas or insulin may increase the risk of hypoglycemia, requiring careful monitoring.

Side Effects of DAPA VILDA 50/5

As with all medications, DAPA VILDA 50/5 may cause some side effects. Most of these are generally mild and transient, but some can be more serious. The common and rare side effects of DAPA VILDA 50/5 include:

Common Side Effects:

• Urinary Tract Infections (UTIs): Since Dapagliflozin increases glucose excretion through urine, it can make the urinary tract more prone to infections.
• Genital Infections: Increased glucose in the urine can also lead to yeast infections in the genital area.
• Headache: Some patients may experience headaches, particularly during the initial phase of treatment.
• Nausea and Vomiting: Gastrointestinal issues such as nausea or vomiting may occur.
• Dizziness: Some patients may feel dizzy, especially when standing up quickly.

Serious Side Effects:

• Kidney Damage: Dapagliflozin can cause dehydration, which can affect kidney function. Monitoring of kidney function is essential, especially in patients with preexisting kidney conditions.
• Hypotension (Low Blood Pressure): As Dapagliflozin has a mild diuretic effect, it can lower blood pressure, leading to dizziness or fainting, particularly in the elderly.
• Ketoacidosis: Though rare, ketoacidosis (a condition in which the body produces high levels of ketones) can occur with SGLT-2 inhibitors.
• Pancreatitis: In very rare cases, DPP-4 inhibitors like Vildagliptin have been associated with pancreatitis.

When to Seek Medical Attention:

If any of the following serious symptoms occur, it is essential to seek immediate medical attention:

• Severe abdominal pain
• Unusual tiredness or weakness
• Dizziness or fainting

Conclusion

DAPA VILDA 50/5 is a combination medication that provides an effective approach to managing type 2 diabetes. With its dual action of Dapagliflozin (an SGLT-2 inhibitor) and Vildagliptin (a DPP-4 inhibitor), this medication helps lower blood glucose levels, reduce body weight, and provide cardiovascular benefits. When used as part of a comprehensive treatment plan, DAPA VILDA 50/5 can greatly improve quality of life for patients with type 2 diabetes. As always, it is important to consult a healthcare provider before starting any new medication and follow the prescribed dosage and guidelines carefully.

About The Author

STERIS HEALTHCARE PVT LTD

Steris Healthcare Pvt Ltd, known as Sterispharma, was founded in February 2018 by a team of experienced professionals in the pharmaceutical industry. Headquartered in Navi Mumbai, the company holds certifications from WHO, GMP, and ISO, reflecting its dedication to maintaining high standards of quality and safety. Sterispharma’s mission is to provide affordable, high-quality medications across India, strictly adhering to WHO guidelines. With the convenience of an online pharmacy, customers can easily order medicines with home delivery options.

For further information 

Email: info@sterispharma.com / contact@sterispharma.com

Call/WhatsApp: 8209542042 , 8824175417

BUY NOW